Liudmila L. Kodach

Dr. Liudmila L. Kodach


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Cell Reports
Verified
Journal Article
Open access
JHJarom Heijmans
Jarom Heijmans
JJJooske F. van Lidth de Jeude
Jooske F. van Lidth de Jeude
BKBon-Kyoung Koo
Bon-Kyoung Koo
SRSanne L. Rosekrans
Sanne L. Rosekrans
MWMattheus C.B. Wielenga
Mattheus C.B. Wielenga
GBGijs R. van Den Brink
Gijs R. van Den Brink
Stem cells generate rapidly dividing transit-amplifying cells that have lost the capacity for self-renewal but cycle for a number of times until they exit the cell cycle and undergo terminal differentiation. We know very little of the type of signals that trigger the earliest steps of stem cell differentiation and mediate a stem cell to transit-amplifying cell transition. We show that in normal intestinal epithelium, endoplasmic reticulum (ER) stress and activity of the unfolded protein response (UPR) are induced at the transition from stem cell to transit-amplifying cell. Induction of ER stress causes loss of stemness in a Perk-eIF2α-dependent manner. Inhibition of Perk-eIF2α signaling results in stem cell accumulation in organoid culture of primary intestinal epithelium. Our findings show that the UPR plays an important role in the regulation of intestinal epithelial stem cell differentiation.

29 August 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
JHJames C. Hardwick
James C. Hardwick
LKLiudmila L. Kodach
Liudmila L. Kodach
GOG. Johan Offerhaus
G. Johan Offerhaus
GBGijs R. van Den Brink
Gijs R. van Den Brink

1 July 2014 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
PVPhilip W. Voorneveld
Philip W. Voorneveld
LKLiudmila L. Kodach
Liudmila L. Kodach
RJRutger J. Jacobs
Rutger J. Jacobs
NLNalan Liv
Nalan Liv
AZA. Christiaan Zonnevylle
A. Christiaan Zonnevylle
JHJames C.H. Hardwick
James C.H. Hardwick

1 May 2008 in Gastroenterology
Verified
Journal Article
Open access
PDF file
LKLiudmila L. Kodach
Liudmila L. Kodach
EWEliza Wiercinska
Eliza Wiercinska
Noel de MirandaNoel de Miranda
Noel de Miranda
SBSylvia A. Bleuming
Sylvia A. Bleuming
AMAlex R. Musler
Alex R. Musler
JHJames C.H. Hardwick
James C.H. Hardwick
Background & Aims: The finding of bone morphogenetic protein (BMP) receptor 1a mutations in juvenile polyposis suggests that BMPs are important in colorectal cancer (CRC). We investigated the BMP pathway in sporadic CRC. Methods: We investigated BMP receptor (BMPR) expression using immunoblotting and sequenced BMPR2 in CRC cell lines. We assessed the expression of BMPRs, SMAD4, and pSMAD1/5/8 in 72 sporadic CRCs using a tissue microarray and immunohistochemistry. We assessed the effect of reintroduction of wild-type BMPR2 on BMP pathway activity and the effect of wild-type or mutated BMPR2 3′ untranslated region (UTR) sequences on protein expression by attachment to pCMV-Luc. Results: BMPR2 and SMAD4 protein expression is abrogated in microsatellite unstable (MSI) and microsatellite stable (MSS) cell lines, respectively. BMPR2 3′UTR is mutated in all MSI and in none of the MSS cell lines. Mutant BMPR2 3′UTR sequences reduced luciferase expression 10-fold compared with wild-type BMPR2 3′UTR. BMPR2 expression is impaired more frequently in MSI CRCs than MSS (85% vs 29%; P < .0001) and shows a mutually exclusive pattern of impaired expression compared with SMAD4. Nine of 11 MSI cancers with impaired expression of BMPR2 have microsatellite mutations. The BMP pathway is inactivated, as judged by nuclear pSMAD1/5/8 expression, in 70% of CRCs, and this correlates with BMPR and SMAD4 loss. Conclusions: Our data suggest that the BMP pathway is inactivated in the majority of sporadic CRCs. In MSI CRC this is associated predominantly with impaired BMPR2 expression and in MSS CRC with impaired SMAD4 expression.

6 May 2011 in Gut
Verified
Journal Article
Closed access
PDF file
LKLiudmila L. Kodach
Liudmila L. Kodach
RJRutger J Jacobs
Rutger J Jacobs
PVPhilip W Voorneveld
Philip W Voorneveld
MWManon E Wildenberg
Manon E Wildenberg
HVHenricus W Verspaget
Henricus W Verspaget
JHJames C H Hardwick
James C H Hardwick
Background: Promoter hypermethylation is an important and potentially reversible mechanism of tumour suppressor gene silencing in cancer. Compounds that demethylate tumour suppressor genes and induce differentiation of cancer cells, but do not have toxic side effects, would represent an exciting option in cancer therapy. Statins are cholesterol-lowering drugs with an excellent safety profile and associated with a reduced incidence of various cancers including colorectal cancer (CRC). The authors have previously shown that statins act by activating tumour suppressive bone morphogenetic protein (BMP) signalling in CRC, increasing expression of BMP2. BMP2 is silenced by hypermethylation in gastric cancer. Aim: To investigate whether BMP2 is methylated in CRC, whether statins can reverse this, and what implications this has for the use of statins in CRC. Methods: Methylation-specific PCR, bisulphite sequencing, immunoblotting, reverse transcription PCR, quantitative PCR, fluorescence-activated cell sorting analysis, an in vitro DNA methyltransferase (DNMT) assay, and cell viability studies were performed on CRC cells. The effect of statins was confirmed in a xenograft mouse model. Results: BMP2 is silenced by promoter hypermethylation in cell lines with the hypermethylator phenotype and in primary tumours. Treatment with lovastatin downregulates DNMT activity, leading to BMP2 promoter demethylation and to upregulation of expression of BMP2 as well as other genes methylated in CRC. Statins alter gene expression, indicating a shift from a stem-like state to a more differentiated state, thereby sensitising cells to the effects of 5-fluorouracil. In a xenograft mouse model, simvastatin treatment induces BMP2 expression, leading to differentiation and reduced proliferation of CRC cells. Conclusions: Statins act as DNMT inhibitors, demethylating the BMP2 promoter, activating BMP signalling, inducing differentiation of CRC cells, and reducing ‘stemness’. This study indicates that statins may be able to be used as differentiating agents in combined or adjuvant therapy in CRC with the CpG island methylator phenotype.

31 July 2006 in Oncogene
Verified
Journal Article
Closed access
CBC L Bos
C L Bos
LKLiudmila L. Kodach
Liudmila L. Kodach
GBG R van Den Brink
G R van Den Brink
SDS H Diks
S H Diks
MSM M van Santen
M M van Santen
JHJ C H Hardwick
J C H Hardwick